These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
96 related items for PubMed ID: 24411923
1. Pre-clinical Crohn's disease: diagnosis, treatment and six year follow-up. Sorrentino D, Avellini C, Geraci M, Vadalà S. J Crohns Colitis; 2014 Jul; 8(7):702-7. PubMed ID: 24411923 [Abstract] [Full Text] [Related]
2. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab. Sloan S, Maxwell P, Salto-Tellez M, Loughrey MB. Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875 [Abstract] [Full Text] [Related]
3. Serum calprotectin as a biomarker for Crohn's disease. Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, Seidel L, Colombel JF, Louis E, GETAID (Groupe d'Étude Thérapeutique Des Affections Inflammatoires Digestives). J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231 [Abstract] [Full Text] [Related]
4. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Ricciardelli I, Lindley KJ, Londei M, Quaratino S. Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560 [Abstract] [Full Text] [Related]
7. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S. Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204 [Abstract] [Full Text] [Related]
10. Buccal localization of Crohn's disease with long-term infliximab therapy: a case report. Ciacci C, Bucci C, Zingone F, Iovino P, Amato M. J Med Case Rep; 2014 Nov 30; 8():397. PubMed ID: 25433368 [Abstract] [Full Text] [Related]
12. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ, International Organization for the Study of Inflammatory Bowel Diseases. Gastroenterology; 2013 Nov 30; 145(5):978-986.e5. PubMed ID: 23954314 [Abstract] [Full Text] [Related]
16. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. Van Assche G, Herrmann KA, Louis E, Everett SM, Colombel JF, Rahier JF, Vanbeckevoort D, Meunier P, Tolan D, Ernst O, Rutgeerts P, Vermeire S, Aerden I, Oortwijn A, Ochsenkühn T. J Crohns Colitis; 2013 Dec 30; 7(12):950-7. PubMed ID: 23411006 [Abstract] [Full Text] [Related]
17. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F, Portela F. BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228 [Abstract] [Full Text] [Related]